We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
-6.61%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$266M
AUM Growth
-$131K
Cap. Flow
+$22.7M
Cap. Flow %
8.53%
Top 10 Hldgs %
48.53%
Holding
95
New
9
Increased
25
Reduced
15
Closed
6

Top Buys

Rank Stock Value
1
FATE icon
Fate Therapeutics
FATE
+$7.86M
2
APLS
Apellis Pharmaceuticals
APLS
+$4.67M
3
TVRD
Tvardi Therapeutics
TVRD
+$4.02M
4
ALEC icon
Alector
ALEC
+$2.2M
5
MGNX icon
MacroGenics
MGNX
+$2.16M

Top Sells

Rank Stock Value
1
QNCX icon
Quince Therapeutics
QNCX
+$2.78M
2
INDP icon
Indaptus Therapeutics
INDP
+$1.8M
3
NXTC icon
NextCure
NXTC
+$1.44M
4
FOMX
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
+$1.41M
5
ARGX icon
argenx
ARGX
+$1.32M

Sector Composition

Rank Sector Weight
1 Healthcare 92.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RIGL icon
76
Rigel Pharmaceuticals
RIGL
$693M
$295K 0.11%
15,770
+2,010
+15% +$41.5K
KALV
77
DELISTED
KalVista Pharmaceuticals
KALV
$287K 0.11%
24,725
– –
ALDX icon
78
Aldeyra Therapeutics
ALDX
$92.3M
$264K 0.1%
50,000
– –
LRMR icon
79
Larimar Therapeutics
LRMR
$413M
$226K 0.09%
25,458
+1,666
+7% +$18.3K
BLCM
80
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$210K 0.08%
20,000
+17,000
+567% +$222K
CDTX
81
DELISTED
Cidara Therapeutics
CDTX
$199K 0.07%
5,000
-5,638
-53% -$190K
KRTX
82
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$183K 0.07%
11,192
+1,192
+12% +$23.2K
EVLO
83
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
$122K 0.05%
+1,000
New +$137K
LCTX icon
84
Lineage Cell Therapeutics
LCTX
$277M
$93K 0.04%
95,000
– –
ADXS
85
DELISTED
Advaxis Inc
ADXS
$93K 0.04%
+350,000
New +$239K
RNTX
86
Rein Therapeutics
RNTX
$63.8M
$67K 0.03%
4,975
– –
ORMP icon
87
Oramed Pharmaceuticals
ORMP
$180M
$51K 0.02%
16,000
– –
INDP icon
88
Indaptus Therapeutics
INDP
$175M
– –
-186
Closed -$1.8M
NXTC icon
89
NextCure
NXTC
$17.9M
– –
-8,008
Closed -$1.44M
QNCX icon
90
Quince Therapeutics
QNCX
$24.4M
– –
-327
Closed -$2.78M
SLGL icon
91
Sol-Gel Technologies
SLGL
$268M
– –
-3,500
Closed -$319K
MORF
92
DELISTED
Morphic Holding, Inc. Common Stock
MORF
– –
-60,000
Closed -$1.19M
NGM
93
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
– –
-6,265
Closed -$92K
1 2 3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
STCG
Speece Thorson Capital Group Minnetonka, Minnesota $439M AUM 10.15% 1-Year Est. Return
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
WAS
Winch Advisory Services Appleton, Wisconsin $438M AUM 17.59% 1-Year Est. Return

DAFNA Capital Management's Q3 2019 Portfolio in Review

As of Q3 2019, DAFNA Capital Management held 95 positions worth $266M, down 0.05% from $266M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

DAFNA Capital Management deployed $22.7M of net new capital in Q3 2019, opening 9 new positions and adding to 25 existing holdings. Its largest new stake was Apellis Pharmaceuticals: 169,800 shares worth $4.09M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 91% a quarter earlier.

On the sell side, the largest reduction was Foamix Pharmaceuticals Ltd. Ordinary Shares, an estimated $1.41M trimmed.

  • DAFNA Capital Management's largest Q3 2019 buy was Apellis Pharmaceuticals: 169,800 shares worth $4.09M.
  • DAFNA Capital Management added most to Fate Therapeutics in Q3 2019, an estimated $7.86M increase.
  • DAFNA Capital Management's biggest Q3 2019 reduction was Foamix Pharmaceuticals Ltd. Ordinary Shares, cutting an estimated $1.41M.
  • DAFNA Capital Management fully exited Quince Therapeutics in Q3 2019, selling an estimated $2.78M.
  • DAFNA Capital Management's ten largest holdings make up 49% of its $266M portfolio in Q3 2019.
  • DAFNA Capital Management opened 9 new positions and closed 6 in Q3 2019.
  • DAFNA Capital Management's portfolio value fell 0.05% quarter-over-quarter to $266M.

Based on DAFNA Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.